In a latest development, Russia's Sputnik V vaccine has shown 94 percent efficacy among those recovered COVID-19 patients. Scientists have opined that there is no evident benefit of using a second dose in previously infected individuals.
According to a study published in the journal Science Direct, it states that 21 days after receiving the first dose of vaccine, 94 percent of participants developed spike-specific antibodies. The study was conducted among healthcare workers in Argentina.
The doctors have however told that the second dose further increases antibody and neutralising capacity.
Researchers say, A single Sputnik V dose elicits higher antibody levels and virus neutralising capacity in previously infected individuals than in new ones receiving the full two-doses."
Notably, a study by Hyderabad’s AIG Hospitals had also claimed that a single dose of Covishield vaccine is sufficient for Covid-recovered patients on account of their robust antibody response. However, the study was conducted on 260 healthcare workers who got the vaccine between January 16 and February 5.
The emergence of Delta variant has added fear to the ongoing struggle against the COVID-19. However, in a sigh of relief, Sputnik V vaccine is around 90% effective against the variant of coronavirus, a report cited Denis Logunov, deputy director of the Gamaleya Institute that developed the vaccine.
The shot was previously found by the researchers to be almost 92% effective against the original strain of coronavirus.
Sputnik V is the third vaccine to be used in India's massive vaccination drive after Covishield by the Serum Institute of India and Bharat Biotech's Covaxin. While Sputnik Light was approved for emergency use in Russia in May, with an efficacy rate of 79.4 per cent, discussions on granting it emergency use approval in India are currently on.
